Expired activity
Please go to the PowerPak homepage and select a course.

The Role of the Clinical Pharmacist in the Management of Multiple Myeloma

Provided by American Academy of CME, Inc.

Supported by an educational grant from Sanofi.

Release date: 05/22/2023
Expiration date: 05/22/2024
Estimated time to complete: 1.50 hours

Clinical Need

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements in the treatment of MM over the last decade, this remains an incurable malignancy and novel therapies continue to be investigated; however, the 5-year relative survival rate has improved since the inclusion of novel therapies such as immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, and BCMA-directed therapy.

This activity provides an overview of recent updates in the treatment of newly diagnosed and relapsed/refractory multiple myeloma, while highlighting the role of the clinical pharmacist in the management of these patients along side members of the care team.


Kathryn Maples, PharmD, BCOP
Multiple Myeloma Clinical Pharmacy Specialist
Adjunct Faculty, Mercer University
PGY2 Oncology Research Coordinator
Emory University

Target Audience

This activity is designed for pharmacists actively engaged in the care of patients with multiple myeloma. Other members of the care team may also participate.

Educational Objectives

After participating in this educational activity, learners should be better able to:

  1. Evaluate the role of newly approved agents and emerging therapies in treating newly diagnosed multiple myeloma (NDMM) as well as relapsed/refractory multiple myeloma (RRMM)
  2. Review clinical guidelines and expert insights in RRMM management
  3. Recognize and mitigate toxicities associated with newly approved agents
  4. Discuss the role of the pharmacists within the patient care team
  5. Develop a patient communication strategy that addresses potential toxicities to mitigate the risk of developing severe complications


acpeIn support of improving patient care, American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity provides 1.50 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-23-014-H01-P, Application

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty Educator and Planner
Kathryn Maples, PharmD, BCOP
Dr. Maples discloses the following relevant financial information with ineligible companies:
Advisory Board/Consultant: GlaxoSmithKline, Pfizer, Janssen, Karyopharm, Sanofi (all have ended)

Planning Committee
John JD Juchniewicz, MCIS, CHCP, FACEHP, Edward Moylan, RPh, Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with any ineligible companies.

Clinical Reviewer
Oxana Megherea, PharmD, BCOP

Dr. Megherea has no relevant financial relationships with any ineligible companies.

This activity will not review off-label or investigational information.


The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CPE credit for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately. For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only pharmacist learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5


For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm


For any questions, please contact: CEServices@academycme.org


© 2023. This CPE-certified activity is held as copyrighted © by American Academy of CME, Inc. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).